At present, five drugs have entered phase 3 development for the treatment of NASH, but the selonsertib Phase 3 program has been recently discontinued
If you want focused fat reduction, appetite control, and metabolic health, Tirzepatide therapy for weight loss may be ideal
Landmark trials show semaglutide (Wegovy) produces 10-15% body weight reduction over 68 weeks, while tirzepatide achieves 20-22% reduction by targeting dual GLP-1 and GIP pathways
In a recently published study of patients with T2DM, semaglutide was found to decrease the vascular uptake of 64 Cu-DOTATE capable of picturing activated macrophages
Preparation and characterization of micellar nanoparticles using crude saponins from five Congolese plant species
Cell cycle arrest is a hallmark of senescent cells (Ogrodnik et al., 2019)